We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy (RICT-LUNG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03416972
Recruitment Status : Recruiting
First Posted : January 31, 2018
Last Update Posted : January 31, 2018
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concurrent chemoradiotherapy. Outcomes remain poor, with 5-year survival of only 20%. Despite the long-held belief that higher radiation doses lead to improved overall survival (OS), the landmark randomized trial (RTOG 0617) showed the opposite. The investigators hypothesize that the inferior survival observed may be due to unexpected heart toxicity as secondary analysis revealed that the heart dose was a strong predictor of inferior OS. Up to now, change in heart function is typically detected histologically, requiring autopsy tissue. Therefore, a non-invasive marker of early heart damage is required. Hybrid PET-MRI has become available in Canada only recently. The ability to simultaneously perform metabolic imaging with functional and tissue imaging allows for novel assessment of heart toxicity. The primary objective is to examine the utility of hybrid PET-MRI and DCE-CT to assess acute changes in heart function and to measure inflammation before, and six weeks after NSCLC radiotherapy. A pilot of 20 patients with Stage I-III NSCLC will be enrolled. The findings of this study will aid in the design of new studies to reassess dose escalation for locally advanced NSCLC while limiting the risk of heart toxicity. FDG PET will be used to simultaneously assess both cardiac inflammation and tumour response. Quantitative DCE-CT will also be used to measure ventilation and perfusion changes in the normal lung and tumour after radiotherapy, providing image data that can comprehensively assess both tumour response and potential toxicity in both the heart and lungs. Such information is crucial in understanding the disease and its response to treatment. This data will also aid in the design of radiation techniques that spare the heart in other patients with any thoracic malignancies, including breast cancer, lymphoma, and esophageal cancer.

Condition or disease Intervention/treatment
Non-small Cell Lung Cancer Radiation Toxicity Radiation: Standard platinum-based chemoradiotherapy

Detailed Description:
The investigators propose a longitudinal imaging pilot study composed of 20 Stage I-III NSCLC patients before, and six weeks after standard radiotherapy using a hybrid 3T-PET/MRI system (Biograph mMR, Siemens Healthcare) and a GE Revolution 256-slice CT scanner. The imaging protocol is designed to detect acute changes in myocardial perfusion, inflammation, edema, left ventricular ejection fraction, normal lung and tumour perfusion, and tumour metabolism. During each imaging session, patients will receive an 18F-FDG PET scan to image macrophage-related inflammation and tumour metabolism, MRI to identify edema, mature fibrosis or scar, and Dynamic contrast enhanced CT (DCE-CT) imaging to image perfusion and (LVEF). All images will be fused and rendered with radiation treatment planning dose distributions. Parameters such as Standard Uptake Value (SUV) will be used to compare PET scans, while heart volume and presence of Gadolinium enhancement will be used to compare MRI scans. Blood flow, blood volume, and permeability will be used to compare CT scans. Blood tests including Erythrocyte Sedimentation Rate (ESR), high sensitivity C-reactive protein, and troponin at each timepoint will also be performed to detect cardiac inflammation. Comparisons between Stage I/II and Stage III patients will allow us to determine whether our metrics for heart changes is radiation related. Relative differences from the six-week time point to baseline will be correlated with the radiation dose distribution to attempt to define a dose-response relationship between radiation dose and cardiac toxicity.

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identification of Acute Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy With Advanced Multi-modality Imaging (RICT-LUNG)
Actual Study Start Date : January 11, 2018
Estimated Primary Completion Date : March 1, 2019
Estimated Study Completion Date : March 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Group/Cohort Intervention/treatment
Stage I-III NSCLC patients
Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
Radiation: Standard platinum-based chemoradiotherapy
Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).

Primary Outcome Measures :
  1. Detection of Imaging Biomarkers of acute cardiac inflammation [ Time Frame: 6 weeks ]
    FDG-PET imaging to detect increase in cardiac inflammation compared to baseline with corresponding blood markers (Erythrocyte Sedimentation Rate (ESR), high sensitivity C-reactive protein, and troponin levels in blood (inflammation)).

  2. Detection of Imaging Biomarkers of acute cardiac perfusion changes [ Time Frame: 6 weeks ]
    DCE-CT imaging to detect changes in acute cardiac perfusion changes compared to baseline.

  3. Detection of Imaging Biomarkers of acute changes in Left-ventricular ejection fraction (LVEF) [ Time Frame: 6 weeks ]
    Contrast-enhanced CT imaging to detect acute changes in LVEF compared to baseline.

  4. Detection of cardiac fibrosis [ Time Frame: 6 weeks ]
    Gadolinium Enhanced MR imaging to detect cardiac fibrosis compared to baseline

Secondary Outcome Measures :
  1. Tumour Response (metabolism) [ Time Frame: 6 weeks ]
    FDG-PET imaging to detect tumour metabolism changes compared to baseline.

  2. Tumour Response (perfusion) [ Time Frame: 6 weeks ]
    DCE-CT imaging to detect changes in tumour perfusion compared to baseline

  3. Acute Changes in Lung Ventilation [ Time Frame: 6 weeks ]
    4D-CT imaging to detect changes in lung ventilation compared to baseline

  4. Acute Changes in Lung Perfusion [ Time Frame: 6 weeks ]
    DCE-CT imaging to detect changes in lung perfusion compared to baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Ultimately, the sample size was based upon practical considerations and that 20 NSCLC patients (10 Stage I/II and 10 Stage III) could be accrued relatively easily from new patient clinics, while sufficiently providing enough evidence to validate the imaging techniques to be used as a non-invasive measure for future clinical trials aimed at reducing or mitigating radiation-induced cardiac toxicity.

Inclusion Criteria:

  • Age 18 or older
  • Ability to provide informed consent
  • Histologically confirmed carcinoma of the lung
  • Stage I-III NSCLC
  • Stage I-II patients to receive 54 Gy in 3 fractions, 55 Gy in 5 fractions, or 60 Gy in 8 fractions (treated every other day)
  • Stage III patient to receive concurrent chemoradiation ( 60 Gy in 30 daily fractions)
  • No prior RT to the thorax
  • ECOG performance status 0-1 within one month of accrual
  • Expected lifespan at least 1 year
  • Negative pregnancy test within one month of accrual if woman is premenopausal
  • Patient presented at multidisciplinary tumor board or quality-assurance rounds
  • Satisfactory pulmonary function tests as determined by the treating radiation oncologist (ie. FEV1 >= 0.8 for Stage III NSCLC and no threshold for Stage I/II).

Exclusion Criteria:

  • Patients receiving Prescription RT dose to anything other than LRCP standards for Stage I-III NSCLC.
  • Prior history of atrial fibrillation
  • Previous coronary bypass surgery
  • Patients with severe reversible airways obstruction
  • Patients with acute coronary syndrome (STEMI/non-STEMI and unstable angina)
  • AV block without pacemaker
  • Patients who are renal insufficient (eGFR <40)
  • Patients with asthma
  • Allergy to iodinated contrast for scans (study subject will be eligible for non-contrast scans)
  • Use of metformin-containing products less than 24 hours prior to CT contrast administration
  • Other contraindications to iodinated contrast media as determined by the research team.
  • Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.
  • Other contraindications to gadolinium contrast media as determined by the research team.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03416972

Contact: Stewart Gaede, PhD 519-685-8600 ext 53144 stewart.gaede@lhsc.on.ca
Contact: Anne O'Connell 519-685-8500 ext 58623 anne.oconnell@lhsc.on.ca

Canada, Ontario
Lawson Health Research Institute Recruiting
London, Ontario, Canada, N6C 2R5
Contact: James Sinfield    519-685-8500 ext 53349    james.sinfield@lhsc.on.ca   
Contact: Albert Gratton    519-685-8500 ext 53233    albert.gratton@lhsc.on.ca   
Principal Investigator: Stewart Gaede, PhD         
Sponsors and Collaborators
Lawson Health Research Institute
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Stewart Gaede, PhD Lawson Health Research Institute

Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT03416972     History of Changes
Other Study ID Numbers: R-17-360
First Posted: January 31, 2018    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries